Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome

ERDOĞAN M. , KARADENİZ M., Alper G. , TAMSEL S. , ULUER H. , Caglayan O., ...More

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol.116, no.3, pp.143-147, 2008 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 116 Issue: 3
  • Publication Date: 2008
  • Doi Number: 10.1055/s-2007-992118
  • Title of Journal : EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
  • Page Numbers: pp.143-147
  • Keywords: thrombin activatable, fibrinolysis inhibitor, cardiovascular risk factors, polycystic ovary syndrome, CORONARY-ARTERY-DISEASE, PREMATURE CAROTID ATHEROSCLEROSIS, TYPE-2 DIABETIC-PATIENTS, TERM-FOLLOW-UP, INSULIN-RESISTANCE, ISCHEMIC-STROKE, YOUNG-WOMEN, MYOCARDIAL-INFARCTION, TAFI LEVELS, ASSOCIATION

Abstract

Objective: We aimed to assess circulating thrombin activatable fibrinolysis inhibitor (TAFI) levels and carotid intima-media thickness (CIMT) in PCOS patients and control sujects. in this study we aimed to evaluate the relation between the levels of TAFI and homocysteine, high sensitive CRP (hsCRP), fibrinogen and CIMT in PCOS patients carrying a potential risk for developing CVD and diabetes and compared with age- and body mass index-matched controls.